Abstract
We studied the dependency of basal 12-lipoxygenase (12-LOX; arachidonate:oxygen 12-oxidoreductase, EC 1.13.11.31) expression and activity on functional protein tyrosine kinase of the epidermal growth factor receptor (EGF-R) and on 12-LOX activity in human A431 epidermoid carcinoma cells. Treatment of cells with inhibitors of high specificity for EGF-R tyrosine kinase, namely PD 153035 and 4,5-dianilinophthalimide (DAPH1), decreased cellular 12-LOX at mRNA, protein, and activity levels in a time- and dose-dependent manner, with PD 153035 being effective at concentrations below 1 microM. After 24-hr incubation with 10 microM PD 153035 or DAPH1, 12-LOX activity dropped to 14% (39%), and 12-LOX protein to 25% (24%) of control level. Inhibition of 12-LOX activity by the compound N-benzyl-N-hydroxy-5-phenylpentanamide (BHPP) also resulted in a substantial decrease in 12-LOX protein expression. 12-LOX mRNA levels were diminished or undetectable by reverse transcription-polymerase chain reaction after cell treatment with these inhibitors. Our results suggest that basal 12-LOX expression in A431 tumor cells largely depends on functional EGF-R tyrosine kinase, and that 12-LOX activity is required in the EGF-elicited intracellular signali...Continue Reading
References
Feb 3, 1977·Nature·J G Rheinwald, H Green
May 7, 1976·Analytical Biochemistry·M M Bradford
Apr 17, 1992·Cell·M P PeppelenboschS W de Laat
Jun 15, 1990·Cell·E P SandgrenD C Lee
Nov 30, 1990·Science·S NishibeG Carpenter
Dec 1, 1991·Cell Regulation·B LiuK V Honn
Mar 15, 1991·The Biochemical Journal·S Clark, M Dunlop
Jan 1, 1991·British Medical Bulletin·W J Gullick
Nov 11, 1991·International Journal of Cancer. Journal International Du Cancer·H ChopraK V Honn
Feb 1, 1991·Journal of Cellular Physiology·G J FisherJ J Baldassare
Oct 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·T IzumiB Samuelsson
Aug 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·C D FunkG A FitzGerald
Sep 1, 1989·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·K V HonnJ D Taylor
Dec 4, 1987·Science·T J VeluD R Lowy
Aug 3, 1994·Journal of the National Cancer Institute·B LiuK V Honn
Sep 1, 1994·Experimental Cell Research·K V HonnB F Sloane
Sep 28, 1995·Biochemical Pharmacology·W C ChangY W Liu
Dec 1, 1994·Cancer Metastasis Reviews·K V HonnW Hagmann
Apr 17, 1995·FEBS Letters·T ArakawaS Yamamoto
Jan 1, 1995·Prostaglandins·W HagmannK V Honn
Aug 19, 1994·Science·D W FryA J Bridges
Mar 15, 1994·Proceedings of the National Academy of Sciences of the United States of America·E BuchdungerN B Lydon
Dec 2, 1993·International Journal of Cancer. Journal International Du Cancer·J TimarK V Honn
Jan 1, 1994·Experimental Cell Research·K V HonnC A Diglio
Dec 1, 1993·Prostaglandins·W HagmannK V Honn
Jun 15, 1993·European Journal of Biochemistry·X S ChenC D Funk
Nov 1, 1996·Experimental Cell Research·W HagmannK V Honn
Citations
Jun 22, 2000·International Journal of Cancer. Journal International Du Cancer·J TimárW Hagmann
Jan 1, 1997·Pathology Oncology Research : POR·Wolfgang Hagmann
Apr 17, 2003·Experimental Eye Research·Paulo OttinoHaydee E P Bazan
Nov 16, 2002·Prostaglandins & Other Lipid Mediators·Tanihiro Yoshimoto, Yoshitaka Takahashi
Nov 4, 2000·Expert Opinion on Investigational Drugs·V E SteeleG J Kelloff
Aug 30, 2002·Biochemical and Biophysical Research Communications·Wei-Gang TongThomas E Adrian
May 15, 2013·Chemical Biology & Drug Design·Carolina MascayanoSteve Perry
Feb 17, 2006·The Prostate·N Patrick McCabeJerzy Jankun